Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.55 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834180 | 0.97 | CNR2 (0.53) | CNR2ALBALDH1A1TSHRHTT | |
| SCHEMBL6834434 | 0.93 | CNR2 (0.50) | CNR2ALBALDH1A1TSHRHTT | |
| SCHEMBL6833794 | 0.89 | CNR2 (0.47) | CNR2ALBALDH1A1TSHRHTT | |
| SCHEMBL6834137 | 0.89 | CNR2 (0.52) | CNR2ALBALDH1A1TSHRHTT | |
| SCHEMBL6835700 | 0.88 | CNR2 (0.48) | CNR2ALBALDH1A1TSHRHTT | |
| SCHEMBL6834130 | 0.85 | CNR2 (0.52) | CNR2ALDH1A1TSHRHTT | |
| SCHEMBL6833056 | 0.85 | CNR2 (0.52) | CNR2ALDH1A1TSHRHTTCNR1 | |
| SCHEMBL6833936 | 0.85 | CNR2 (0.47) | CNR2ALBALDH1A1TSHRHTT | |
| SCHEMBL6834081 | 0.84 | CCR2 (0.55) | CNR2ALBCNR1 | |
| SCHEMBL6818878 | 0.84 | ALB (0.56) | CNR2ALBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CNR2 3495/4885ALB 1417/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.